Multi-Agent Based Automation of Literature Surveillance for Pharmacovigilance

Manual literature surveillance for pharmacovigilance is a high-labor, low-consistency bottleneck that risks delayed signal detection and regulatory non-compliance. A custom multi-agent workflow automates the continuous scanning of PubMed, conference abstracts, and preprint servers for articles related to your drug products. It extracts safety-relevant findings, summarizes them against product labeling, and triages potential signals to safety scientists with explicit rationale. This directly reduces the time-to-detection for emerging risks and creates a defensible, documented audit trail for health authority inspections, turning a reactive administrative task into a proactive, scalable operating model.

Implementation requires orchestrating specialized agents—for retrieval, entity recognition, and causal inference—within a framework like LangGraph, integrated with your safety database (e.g., Oracle Argus Safety, Veeva). The architecture must include configurable confidence thresholds, mandatory human-in-the-loop review for high-severity signals, and an immutable explanation layer linking each triage decision to source text and internal rules. This ensures the workflow meets ICH E2B and FDA 21 CFR Part 11 requirements for electronic records, while providing the operational leverage to monitor thousands of publications without proportional headcount growth.

This orchestration engine automates the continuous scanning of scientific literature and conference abstracts for potential drug safety signals. It replaces manual, batch-based review processes, improving detection sensitivity and ensuring compliance with regulatory monitoring mandates like GVP Module VI. The operational upside comes from faster signal identification, reduced administrative burden on safety scientists, and a fully documented audit trail linking each article to a triage decision and its supporting evidence.

Implementation integrates with existing PV systems like Argus or ArisG, using LangGraph or a custom state machine for agent coordination. Each agent's logic—scoring, summarization, routing—is containerized for independent scaling and validation. Critical controls include human-in-the-loop review gates for high-confidence signals, configurable confidence thresholds, and immutable logs capturing each agent's input, logic, and output to satisfy audit requirements from regulators like the FDA or EMA.

Phase 1 establishes the foundational data pipeline and a single-agent proof of concept. We integrate with PubMed, CrossRef, and conference abstract APIs to create a centralized ingestion layer. A primary 'Screener Agent' is deployed to perform initial relevance filtering against a dynamic drug product lexicon, tagging articles for downstream processing. This MVP delivers immediate value by automating literature aggregation and basic triage, providing a testbed for data quality and agent performance before scaling complexity. The focus is on building a robust, observable ingestion backbone.

Phase 2 introduces orchestration via LangGraph or a custom scheduler, deploying specialized agents for signal detection and summarization. This layer applies MedDRA coding, cross-references internal safety data, and generates auditable rationales. Articles are scored and routed into a prioritized review queue. Phase 3 integrates the human review interface within platforms like Veeva Safety or ArisGlobal, embedding agent outputs for scientist validation. Approved cases trigger automated E2B (R3) draft generation. Each phase is governed by validation checkpoints, exception routing rules, and comprehensive model audit logs to satisfy FDA 21 CFR Part 11 and GVP requirements.

A production pharmacovigilance surveillance system requires a phased, controlled rollout to manage risk and build user trust. Implementation begins with a pilot on a single, high-priority drug product and a curated set of low-risk literature sources (e.g., PubMed). The architecture is deployed in a 'human-in-the-loop' mode where all AI-generated signal summaries and triage recommendations are mandatorily reviewed by a safety scientist before any action is logged in the safety database (e.g., Argus, ARISg). This initial phase validates the agent's precision, refines prompting logic, and establishes the baseline workflow for exception handling and feedback incorporation.

Governance is enforced through immutable audit trails that link every article, AI analysis, reviewer decision, and final case entry. The orchestrator (e.g., LangGraph) manages state, routes exceptions, and enforces approval gates before any write operation to the system of record. Rollout expands to additional drug portfolios and literature sources only after achieving predefined performance metrics (e.g., >95% reviewer agreement on triage priority). Continuous monitoring tracks agent drift, and a formal change control process governs any updates to the prompting logic or data sources to maintain regulatory defensibility.

This multi-agent system automates the labor-intensive, mandatory process of literature surveillance, where safety scientists manually review thousands of publications for potential adverse drug reactions. The operational upside comes from a 70-80% reduction in manual screening time, allowing experts to focus on high-signal triage and complex case assessment. The architecture must integrate with PubMed, Embase, and internal safety databases, using specialized agents for retrieval, relevance scoring, and evidence summarization to create a defensible, rationale-backed workflow.

Implementation requires building orchestration logic—typically with LangGraph or a custom scheduler—to manage agent handoffs, data persistence, and exception routing. Critical controls include predefined signal thresholds, mandatory human review for novel mechanisms, and immutable audit logs linking every article to its processing rationale. The system integrates with pharmacovigilance platforms like Argus Safety or Veeva PV to auto-create cases, ensuring the workflow feeds directly into regulated reporting pipelines without creating compliance gaps.